Article

Bray, G. A. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J. Clin. Endocrinol. Metab. 93, S81-S88

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA.
Journal of Clinical Endocrinology & Metabolism (Impact Factor: 6.21). 11/2008; 93(11 Suppl 1):S81-8. DOI: 10.1210/jc.2008-1294
Source: PubMed

ABSTRACT

Obesity results from a prolonged small positive energy balance, and its treatment needs to reverse this imbalance.
Citations retrieved from PubMed and The Handbook of Obesity 2008 were selected to illustrate the points.
Many different diets have been tried to treat obesity, and weight loss occurs with all of them. There is currently no evidence that clearly supports a superiority of one macronutrient composition for diets used for weight loss. The principal effect seems to be the degree of adherence to the prescribed calorie reduction. Lifestyle strategies to modify eating behavior can be used in individual counseling sessions or in groups, both of which are important in helping patients modify their patterns of eating. Physical activity is particularly important in helping patients maintain a weight loss once achieved and is less valuable for weight loss itself. Food intake is controlled through many different mechanisms, but only a few drugs have been developed that tap these mechanisms. Orlistat, which blocks intestinal lipase, is one; sibutramine, a serotonin-norepinephrine reuptake inhibitor, is a second. Surgical approaches provide the most dramatic weight loss and have been demonstrated to reduce long-term mortality and reduce the incidence of diabetes.
Weight loss can be achieved by many methods, but the surgical procedures appear to be the most durable.

0 Followers
 · 
6 Reads
    • "Obesity is a multi-factorial disease leading to reduce life expectancy. Therapeutic strategies for obese patients are usually characterized by a low proportion of successes, especially in the long term [1]. Motivational Interviewing (MI) is a directive, person-centered approach designed to activate motivation for change by helping patients to explore and resolve ambivalence surrounding modification of complex behaviors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A pilot uncontrolled study aimed at investigating the efficacy of a motivational enhancement therapy adapted for obesity was conducted on 71 obese patients (59 females). Treatment consisted of 5 weekly group sessions and 3 weekly individual sessions. Outcome measures included Treatment, Motivation and Readiness test (TREMORE) and anthropometric measures. Patients showed a significant reduction of all anthropometric parameters (with exception of waist circumference), and a significant improvement of TREMORE scores at the end of the treatment. The motivational interviewing program applied in the current study appears to be effective and consistent with both patient recommendations and health care clinic demands. Copyright © 2015 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
    No preview · Article · Jul 2015 · Obesity Research & Clinical Practice
  • Source
    • "Obesity, characterized by excessive fat accumulation in the form of triglycerides (TG) in adipose tissue and ectopic TG deposition in other organs, is a primary risk factor for type 2 diabetes, cardiovascular diseases, and other comorbidities. Current pharmacological treatments are inadequate for weight loss [1]. Thus, a more detailed knowledge of pathways that influence energy homeostasis is necessary for the development of safe, more effective obesity and diabetes therapies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diacylglycerol acyltransferase-1 (DGAT1) is a potential therapeutic target for treatment of obesity and related metabolic diseases. However, the degree of DGAT1 inhibition required for metabolic benefits is unclear. Here we show that partial DGAT1 deficiency in mice suppressed postprandial triglyceridemia, led to elevations in glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) only following meals with very high lipid content, and did not protect from diet-induced obesity. Maximal DGAT1 inhibition led to enhanced GLP-1 and PYY secretion following meals with physiologically relevant lipid content. Finally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further enhancements in active GLP-1 in mice and dogs. The current study suggests that targeting DGAT1 to enhance postprandial gut hormone secretion requires maximal inhibition, and suggests combination with DPP-4i as a potential strategy to develop DGAT1 inhibitors for treatment of metabolic diseases.
    Full-text · Article · Jan 2013 · PLoS ONE
  • Source
    • "Theoretically, improving NAFLD via weight loss is an ideal approach in obese or overweight people because other complications are simultaneously ameliorated. Of several commonly used antiobesity medications [134], orlistat and sibutramine are available for long-term prescription [135, 136]. Orlistat inhibits dietary triglyceride hydrolysis in the gut, occasionally with mild gastrointestinal symptoms, resulting in a substantial decrease in fat absorption. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain.
    Full-text · Article · Dec 2012
Show more